Clinical Trials on Leucemia mieloblástica aguda sin maduración

Total 530 results

Versailles Hospital

Recruiting

PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS (PONAZA)

CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE | CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS

France
Grupo Cooperativo de Hemopatías Malignas

Recruiting

Myeloid Mutations Register in R/R CML

Chronic Myeloid Leukaemia Recurrent | Chronic Myeloid Leukemia, in Relapse

Mexico
Institut Paoli-Calmettes
INATHERYS

Recruiting

Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia (INA03)

Acute Lymphoblastic Leukemia, in Relapse | Acute Myeloid Leukemia, in Relapse | Mixed Phenotype Acute Leukemia | Acute Lymphoblastic Leukemia Recurrent | Acute Myeloid Leukaemia Recurrent

France
Nanfang Hospital of Southern Medical University

Recruiting

Decitabine and HQP1351-based Chemotherapy Regimen for the Treatment Advanced CML (Case-Only)

Chronic Myeloid Leukemia in Myeloid Blast Crisis | Chronic Myeloid Leukaemia Transformation | Chronic Myeloid Leukemia - Accelerated Phase | Chronic Myeloid Leukemia in Lymphoid Blast Crisis

China
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART C)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART A)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies (HEM-iSMART D)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Hospices Civils de Lyon

Completed

Early Palliative Care in Patient With Acute Leukaemia (Pablo Hemato)

Acute Leukaemia in Relapse

France
Angiocrine Bioscience
California Institute for Regenerative Medicine (CIRM)

Completed

Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia in Remission | Other Acute Leukemias

United States
University of Southern California
National Cancer Institute (NCI)

Withdrawn

Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission

Adult Acute Myeloid Leukemia in Remission | Childhood Acute Myeloid Leukemia in Remission

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia

Adult Acute Myeloid Leukemia in Remission | Childhood Acute Myeloid Leukemia in Remission

United States
University of Utah

Recruiting

Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia (CLL) With History of Non-melanoma Skin Cancers (NMSC)

Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia

Squamous Cell Carcinoma of the Skin | Recurrent Skin Cancer | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia

United States
Cairo University

Completed

Aerobic Versus Resistive Training on Functional Capacity in Acute Myeloid Leukemia

Acute Myeloid Leukemia in Remission

Egypt
Osaka University
Japan Agency for Medical Research and Development

Recruiting

Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients.

Acute Myeloid Leukemia in Remission

Japan
Ge Zheng

Recruiting

Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML

Acute Myeloid Leukemia in Remission

China
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Active, not recruiting

High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML

Acute Myeloid Leukemia, in Relapse

United States
Peking University People's Hospital
Beijing JD Biotech Co. LTD.

Recruiting

Off-the-shelf CD123 CAR-NK for R/R AML

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Xuzhou Medical University

Recruiting

Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Bio-Path Holdings, Inc.

Recruiting

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
Oryzon Genomics S.A.

Recruiting

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) (FRIDA)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
University Hospital, Antwerp

Recruiting

Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

Belgium
Medical College of Wisconsin

Recruiting

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
Nantes University Hospital

Recruiting

Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT (FLUCLORIC)

Acute Myeloid Leukemia in Remission

France
University of Freiburg

Completed

Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment

Acute Myeloid Leukemia, in Relapse

Germany
University of Pennsylvania

Active, not recruiting

CD123 Redirected T Cells for AML in Pediatric Subjects

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, Pediatric

United States
Xuzhou Medical University

Recruiting

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Terrence J Bradley, MD
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...

Recruiting

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia (VenBom)

Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse

United States
Advesya SAS

Not yet recruiting

An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia (RESOLVE AML001)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

France, Sweden, Spain, Germany
Georgetown University
National Heart, Lung, and Blood Institute (NHLBI); Jazz Pharmaceuticals

Recruiting

Phase IB/II of CPX-351 for Relapse Prevention in AML

Acute Myeloid Leukemia (AML) in Remission

United States
Keystone Nano, Inc
Milton S. Hershey Medical Center; University of Virginia

Not yet recruiting

Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (KNAN2001)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory

United States
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Unknown

INFUSION OF ALLOREACTIVE NATURAL KILLER (NK) CELLS AS CONSOLIDATION STRATEGY FOR ACUTE MYELOID LEUKEMIA PATIENTS (NKAML)

Adult Acute Myeloid Leukemia in Remission

Italy
King Faisal Specialist Hospital & Research Center

Recruiting

Comparing Post-Transplant Cyclophosphamide as GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients (PTCy-PMAT)

Acute Myeloid Leukemia (AML) in Remission | Acute Lymphoblastic Leukemia (ALL) in Complete Remission

Saudi Arabia
The First Affiliated Hospital of Soochow University

Recruiting

AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

Acute Myeloid Leukemia (AML) in Remission

China
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic CLL Study Group

Active, not recruiting

A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Chronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in Remission

Netherlands, Belgium, Denmark, Finland, Norway, Sweden
Stanford University

Withdrawn

Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant

Adult Acute Myeloid Leukemia in Remission | Acute Myeloid Leukemia With Gene Mutations
Vastra Gotaland Region

Recruiting

Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML (SCRIPT-AML)

Stem Cell Transplantation | Acute Myeloid Leukemia (AML) in Remission

Belgium, Denmark, Finland, Hong Kong, Israel, Lithuania, Netherlands, Norway, Spain, Sweden
Mendus
Amsterdam UMC, location VUmc

Active, not recruiting

Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia (ADVANCE-II)

Acute Myeloid Leukemia in Remission

Norway, Netherlands, Sweden, Finland, Germany
Shanghai Fosun Pharmaceutical Industrial Development...

Terminated

A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML

Advanced Cancer | Solid Tumors | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States, Australia
Washington University School of Medicine

Recruiting

Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant

Acute Myeloid Leukemia in Children

United States
Princess Maxima Center for Pediatric Oncology
European Commission

Recruiting

CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients

Acute Myeloid Leukemia in Children

Netherlands
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Recruiting

Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events (MEASURE)

Acute Myeloid Leukemia in Remission

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Culturally Adapted Parenting Intervention for Spanish-Speaking Parents in Improving Outcomes of Younger Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Survivors at Risk for Late Neurocognitive Effects

Childhood Acute Myeloid Leukemia in Remission | Cancer Survivor | Childhood Acute Lymphoblastic Leukemia in Remission | Cognitive Side Effects of Cancer Therapy

United States
Princess Maxima Center for Pediatric Oncology
Daiichi Sankyo

Recruiting

CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients (CHIP-AML22/Q)

Acute Myeloid Leukemia in Children

Netherlands
Sunshine Lake Pharma Co., Ltd.

Completed

Clifutinib Food Effect Study in Healthy Subjects

Acute Myeloid Leukemia in Children

China
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute

Active, not recruiting

A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse

United States
Menarini Group

Terminated

Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia (ARMY)

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse

France, Germany, Italy, Spain, Belgium
Caribou Biosciences, Inc.

Recruiting

CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AMpLify)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
University of Pennsylvania

Recruiting

Lentivirally Redirected CD123 Autologous T Cells in AML

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Adult | Acute Myeloid Leukemia, Refractory

United States
Seattle Children's Hospital
2seventy bio

Recruiting

PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States

Clinical Trials on Leucemia mieloblástica aguda sin maduración

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations